Elemental diet decreases inflammation and improves symptoms in adult eosinophilic oesophagitis patients

Atopic Dermatitis

Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: Results from a randomized, placebo-controlled clinical trial

Br J Dermatol.

Tsianakas A, Luger TA, Radin A

doi: 10.1111/bjd.15905.

Atopic Dermatitis

Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life, and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomised trial

J Eur Acad Dermatol Venereol

Wollenberg A, Nakahara T, Maari C, Peris K, Lio P, Augustin M, Silverberg JI, Rueda MJ, DeLozier AM, Pierce E, Yang FE, Sun L, Ball S, Tauber M, Paul C

doi: 10.1111/jdv.17278

COMMENTED

Psoriasis

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies

Am J Clin Dermatol.

Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, You Y, Papp KA

doi: 10.1007/s40257-018-0396-z.

Atopic Dermatitis

Dupilumab with concomitant topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: a placebo-controlled, randomized phase 3 clinical trial (LIBERTY AD CAFÉ)

Br J Dermatol.

de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork M, Radin A, Zhang Q, Akinlade B, Gadkari A, Eckert L, Hultsch T, Chen Z, Pirozzi G, Graham NMH, Shumel B

doi: 10.1111/bjd.16156.

COMMENTED

Atopic Dermatitis

The Oral JAK/SYK Inhibitor ASN002 Demonstrates Efficacy and Improves Associated Systemic Inflammation in Patients with Moderate-to-Severe Atopic Dermatitis: Results from a Randomised, Double-Blind, Placebo-Controlled Study

Br J Dermatol.

Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J, Tyring S, Pariser D, Sofen H, Dhawan S, Zook M, Zammit DJ, Usansky H, Denis L, Rao N, Song T, Pavel AB, Guttman-Yassky E

doi: 10.1111/bjd.17932.

Allergic Diseases

Increased Group 2 Innate Lymphoid Cells Are Correlated with Eosinophilic Granulocytes in Patients with Allergic Airway Inflammation

Int Arch Allergy Immunol.

Yu QN, Tan WP, Fan XL, Guo YB, Qin ZL, Li CL, Chen D, Lin ZB, Wen W, Fu QL

doi: 10.1159/000488050.

Psoriatic Arthritis

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)

Rheumatology (Oxford).

Gottlieb AB, Strand V, Kishimoto M, Mease P, Thaçi D, Birt J, Lee CH, Shuler CL, Lin CY, Gladman DD

doi: 10.1093/

Rheumatoid Arthritis

Diet and Rheumatoid Arthritis Symptoms: Survey Results From a Rheumatoid Arthritis Registry

Arthritis Care Res (Hoboken).

Tedeschi SK, Frits M, Cui J, Zhang ZZ, Mahmoud T, Iannaccone C, Lin TC, Yoshida K, Weinblatt ME, Shadick NA, Solomon DH

doi: 10.1002/acr.23225.

Rheumatoid Arthritis

Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation

Transl Res.

Ruiz-Limón P, Ortega R, Arias de la Rosa I, Abalos-Aguilera MDC, Perez-Sanchez C, Jimenez-Gomez Y, Peralbo-Santaella E, Font P, Ruiz-Vilches D, Ferrin G, Collantes-Estevez E, Escudero-Contreras A, López-Pedrera C, Barbarroja N

doi: 10.1016/j.trsl.2016.12.003.

Related content

Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: Results from a randomized, placebo-controlled clinical trial

Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life, and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomised trial

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies

Dupilumab with concomitant topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: a placebo-controlled, randomized phase 3 clinical trial (LIBERTY AD CAFÉ)

The Oral JAK/SYK Inhibitor ASN002 Demonstrates Efficacy and Improves Associated Systemic Inflammation in Patients with Moderate-to-Severe Atopic Dermatitis: Results from a Randomised, Double-Blind, Placebo-Controlled Study

Increased Group 2 Innate Lymphoid Cells Are Correlated with Eosinophilic Granulocytes in Patients with Allergic Airway Inflammation

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)

Diet and Rheumatoid Arthritis Symptoms: Survey Results From a Rheumatoid Arthritis Registry

Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation